US 10,519,506 B2 · Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer

Abstract

The present invention includes methods and biomarkers for diagnosing or detecting colorectal cancer metastasis in a human subject by comparing the Alu repeat methylation level in the biological sample to an Alu repeat methylation control level from a normal non-cancerous sample from the human subject, wherein a decrease in the Alu repeat methylation level is indicative of colorectal cancer and colorectal cancer metastasis. The invention also includes methods and biomarkers for diagnosing or detecting colorectal cancer (CRC) metastasis in a human subject by determining a level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample from the one or more biological samples; and comparing the level of expression of let-7i, miR-10b, miR-320a, and miR-221 in the sample with the level of expression of let-7i, miR-10b, miR-320a, and miR-221 from normal colorectal tissue, wherein high expression of at least on of let-7i or miR-320a is indicative of a good prognosis for the CRC, while the low expression of at least one of miR-10b or miR-221 is indicative of a good prognosis for the CRC or CRC metastasis.

Claims20

Dependent claims

A method for treating a patient with Stage IV colorectal cancer, the method comprising:

treating the patient with adjunctive therapy;
wherein the patient comprises one that has been determined to have a statistically significantly lower expression level of let-7i and/or miR-320a in a biological sample from the patient, as compared to a control sample, and/or when the patient was determined to have a statistically significantly higher expression level of miR-10b, miR-221, miR-200c, and/or miR-203 in a biological sample from the patient, as compared to a control;
wherein the expression level in the biological sample was determined by performing digital color-coded barcode technology analysis, microarray expression profiling, PCR, reverse transcriptase PCR, reverse transcriptase real-time PCR, quantitative real-time PCR, end-point PCR, multiplex end-point PCR, cold PCR, ice-cold PCR, mass spectrometry, or nucleic acid sequencing on nucleic acids from the biological sample from the patient;
wherein the control sample is a reference level of expression from a biological sample of a patient with Stage I colorectal cancer.

1 more element

Dependencies are inferred from the claim text.

Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer

Life of this patent

Identification of metastasis-specific miRNA and hypomethylation signatures in human colorectal cancer

Life of this patent

Abstract

Claims20